[Federal Register: September 25, 2003 (Volume 68, Number 186)]
[Notices]
[Page 55393-55394]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr25se03-60]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60Day-03-120]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call the CDC Reports
Clearance Officer at (404) 498-1210.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Send comments to Anne O'Connor, CDC
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24,
Atlanta, GA 30333. Written comments should be received within 60 days
of this notice.
Proposed Project: Survey of Primary Care Physicians Regarding
Prostate Cancer Screening--New--National Center for Chronic Disease
Prevention and Health Promotion (NCCDPHP), Centers for Disease Control
and Prevention (CDC).
Prostate cancer is the most common cancer in men and is the second
leading cause of cancer deaths, behind lung cancer. The American Cancer
Society estimates that there will be about 220,900 new cases of
prostate cancer and about 28,900 deaths in 2003. Although prostate
cancer deaths have declined over the past several years, it ranks fifth
among deaths from all causes. The digital rectal examination (DRE) and
prostate specific antigen (PSA) test are used to screen for prostate
cancer. Screening is controversial and many are not in agreement as to
whether prostate specific antigen (PSA) based screening, early
detection, and later treatment increases longevity. Although major
medical organizations are divided on whether men should be routinely
screened for this disease, it appears that all of the major
organizations recommend discussion with patients about the benefits and
risks of screening.
The purpose of this project is to develop and administer a national
survey to a sample of American primary care physicians to examine
whether or not they: screen for prostate cancer using (PSA and/or DRE),
recommend testing and under what conditions, discuss the tests and the
risks and benefits of screening with patients, and if their screening
practices vary by factors such as age, ethnicity, and family history.
This study will examine demographic, social, and behavioral
characteristics of physicians as they relate to screening and related
issues, including knowledge and awareness, beliefs regarding efficacy
of screening and treatment, frequency of screening, awareness of the
screening controversy, influence of guidelines from medical, practice
and other organizations, and participation and/or willingness to
participate in shared decision-making. There is no cost to respondents.
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden/ Total burden
Respondents respondents responses/ response (in (in hours)
respondents hours)
----------------------------------------------------------------------------------------------------------------
Primary Care Physician.......................... 1,500 1 40/60 1,000
-----------------
Total....................................... .............. .............. .............. 1,000
----------------------------------------------------------------------------------------------------------------
[[Page 55394]]
Dated: September 19, 2003.
Thomas A. Bartenfeld,
Acting Associate Director for Policy, Planning and Evaluation, Centers
for Disease Control and Prevention.
[FR Doc. 03-24275 Filed 9-24-03; 8:45 am]
BILLING CODE 4163-18-P